Editas Medicine, Inc. (EDIT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Editas Medicine, Inc. (EDIT) closed at USD 2.27 on 2026-10-14, a change of -28.4 % over the past year, with a market capitalization of USD 374.74M.

Editas Medicine, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Editas Medicine, Inc. key figures

Previous close

USD 2.27 (2026-10-14)

1-year change

-28.4 %

Market cap

USD 374.74M

Enterprise value

USD 178.6M

P/E ratio (trailing)

-3.39

P/E ratio (forward)

-3.24

EPS (trailing)

-0.72

EPS (forward)

-0.75

PEG ratio

n/a

Price to book

3.56

Revenue growth

232.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

12.47

Employees

87

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Editas Medicine, Inc. and compare it with other stocks.